Pfizer tests new cancer drug combo in early human trial
NCT ID NCT06870487
Summary
This early-stage study is testing the safety of a new cancer drug called PF-08046032, both by itself and combined with another drug called sasanlimab. It involves a small group of adults with advanced or spreading cancers, including certain lymphomas and solid tumors like lung cancer and melanoma. The main goal is to find safe dose levels and understand the side effects before testing if the treatment is effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutchinson Cancer Center.
Seattle, Washington, 98109, United States
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
University of Washington Medical Center- Montlake
Seattle, Washington, 98195, United States
Conditions
Explore the condition pages connected to this study.